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Abstract
The aim of this study was to evaluate survival 
time for AIDS patients 13 years and older in the 
South and Southeast regions of Brazil, according 
to socio-demographic, clinical, and epidemio-
logical characteristics. The sample was selected 
from all cases diagnosed in 1998 and 1999 and 
notified to the Epidemiological Surveillance Sys-
tem of the National STD/AIDS Program. Use of a 
questionnaire allowed analyzing 2,091 patient 
charts. Based on the Kaplan-Meier method, es-
timated survival was at least 108 months after 
diagnosis in 59.5% of patients in the Southeast 
and 59.3% in the South. Cox regression models 
showed, in both regions, an increase in survival 
in patients on antiretroviral therapy, those clas-
sified as AIDS cases according to the CD4 T-cell 
criterion, females, and those with more school-
ing.  Other factors associated with longer survival 
in the Southeast were: white skin color, no history 
of tuberculosis since the AIDS diagnosis, negative 
hepatitis B serology, and access to a multidisci-
plinary health team. In the South, age below 40 
years was associated with longer survival.
Acquired Immunodeficiency Syndrome; Survi-
vorship (Public Health); Anti-Retroviral Agents; 
Mortality
Introduction
Since identification of the first AIDS cases in 
Brazil in the early 1980s, the disease has spread 
slowly and steadily throughout the country, be-
coming a veritable mosaic of epidemics. In the 
last two decades, HIV transmission has reached 
marginalized and vulnerable populations, with 
an increase in the occurrence of AIDS cases in 
municipalities (counties) outside the large met-
ropolitan areas, among heterosexuals, especially 
women, a reduction in injecting drug users (IDU), 
and stabilization among young people 1. 
There has been a trend towards stabilization 
of AIDS incidence in Brazil, especially since 1997, 
but with significant regional differences. The last 
decade has witnessed a decrease in incidence 
rates in the South and Southeast regions of the 
country and an increase in the North, Northeast, 
and Central. In the Southeast, the incidence rate 
of 24.4 per 100 thousand in 1999 decreased to 
16.8 per 100 thousand in 2005. There was also a 
reduction in the South, although not as sharp, 
from 22.2 per 100 thousand inhabitants in 1999 
to 20.0 per 100 thousand in 2005 2.
From 1980 to 2008, a total of 432,890 AIDS 
cases were reported in the entire country, of 
which 80,929 resided in the South and 268,398 
in the Southeast. These two geographic regions 
accounted for 80.7% of all AIDS cases in Brazil 2. 
Of all the cases, 96.8% were 13 years or older at 
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time of AIDS diagnosis, thus defined as adult 
cases under the Brazilian classification 3. 
Substantial changes in the morbidity and 
mortality caused by HIV infection were widely 
documented after introduction of highly active 
antiretroviral therapy (HAART) 4,5,6,7. 
The AIDS mortality rate in Brazil dropped 
from 9.6 deaths per 100 thousand inhabitants 
in 1996 to 6 per 100 thousand in 2006. However, 
during this same period the rates in the North 
and Northeast showed an important increase, 
along with a slight rise in the South. The decline 
in Brazilian mortality rates resulted from a sharp 
drop in the rate in the Southeast (from 16.3 in 
1996 to 7.4 per 100 thousand in 2006) and in part 
to a reduction in the Central 2. 
With the use of the new therapy, the clini-
cal spectrum of patients with HIV infection was 
expanded to include not only opportunistic 
diseases, but also clinical conditions associated 
with adverse effects of therapy, as well as chronic 
diseases with progressively increasing incidence 
during aging 8,9. The longer survival of individu-
als with HIV infection/AIDS has been observed 
not only in developed countries, but also in poor 
regions of the world where access to HAART has 
been expanded, as in some countries of Sub-
Saharan Africa 10. A 50% reduction in mortality 
was observed in a cohort study in New York, in 
patients undergoing HAART from 1995 to 2000 8.
Brazil experienced a reduction of approxi-
mately 50% in deaths and 80% in hospitalizations 
due to AIDS, from 1995 to 2001 1,4,11. Median sur-
vival of AIDS patients over 12 years of age was 
5.1 months from 1982 to 1989 12. According to 
Marins et al. 13, individuals diagnosed in 1995 
has a median survival of 16 months, and those 
diagnosed in 1996 had a median survival of 58 
months. This noteworthy increase in survival 
has been attributed to the Ministry of Health’s 
policy for care and prevention since the 1990s, 
investing in universal, free access to antiretroviral 
drugs, widespread availability of diagnostic tests 
and case follow-up, training of health profession-
als, and the creation of a laboratory network for 
monitoring drug resistance 1,13. 
Investments in prevention and care for AIDS 
patients in Brazil require evaluations of their real 
impact. Updating the patient survival analyses 
can contribute to monitoring the epidemic’s dy-
namics and measuring the needs for care, as well 
as assessing strategies for control of the disease 
in the country.
The aim of this study was to evaluate survival 
time according to socio-demographic, clinical, 
and epidemiological characteristics of AIDS pa-
tients diagnosed in 1998 and 1999 in the South 
and Southeast regions of Brazil.
Method
A non-concurrent cohort study was performed 
in a sample of AIDS patients 13 years and older, 
residing in the South and Southeast regions of 
Brazil, diagnosed in 1998 and 1999 and recorded 
in the Information System on Diseases of Noti-
fication (SINAN). The database was provided by 
the Brazilian National STD/AIDS Program.
Starting with all cases reported in the two re-
gions in 1998 and 1999, the sample selection ini-
tially excluded cases: from municipalities (coun-
ties) with fewer than 40 notifications during the 
period, representing 18% of the total; with AIDS 
first diagnosed at death; from an unknown noti-
fication unit; or with date of diagnosis later than 
death or notification. After these exclusions, the 
remaining cases totaled 29,600 and 8,797, distrib-
uted across 90 and 33 municipalities, respective-
ly, in the Southeast and South.
Sample sizes were determined to allow verifi-
cation of statistical significance between different 
median survival times in population subgroups: 
from 58 to 70 months in the Southeast and 58 to 
74 months in the South, whereas 58 months was 
the estimated median survival time in a previous 
study 13. 
To test the hypothesis that the risk of dying 
within a given time span was the same in two 
population subgroups (I and II), the number de 
cases to be included in the study was calculated 
as the ratio between the number of deaths need-
ed to test the hypothesis and the probability of 
dying during the study period 14. The number of 
deaths was expressed as:
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where α  = 0.05; β  = 0.20; 2αz  and βz  the 
points on the standardized normal curve and πI =
πII = 0.5 the proportions of cases in groups I and 
II. The probability of dying was expressed as:
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where a = 24 months is the study’s case inclu-
sion period; f = 72 months is the follow-up pe-
riod; and the term following a and S  expresses 
the estimated mean values for survival functions 
in groups I and II.
The calculations were performed with the 
Power and Precision software (Biostat Inc., En-
glewwod, USA) and indicated the need for a sam-
ple of 1,484 patients in the Southeast region and 
898 in the South. Since the study predicted losses 
on the order of 30%, larger numbers of patients 
were selected: 2,214 and 1,280.
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Composition of the sample for each stratum 
(region) used two-stage cluster sampling: mu-
nicipalities and patients. Municipalities were se-
lected with probability proportional to size, de-
fined as the number of notifications to SINAN by 
health units. Before beginning the selection, the 
municipalities that lacked the minimum number 
of notifications to be picked in the second stage 
were grouped with other, larger municipalities. 
Thus, the primary sampling units became the 
municipalities or sets of municipalities. Eigh-
teen were selected in the Southeast and 10 in the 
South. In the second stage, 123 and 128 patients 
were selected in each primary unit in the South-
east and South, respectively. The sampling frac-
tions were:  
369,13
1123
29600
18
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f    in the Southeast and
873,6
1128
8797
10
	

	
i
i
N
N
f     in the South, where
Ni is the number of AIDS cases in the municipal-
ity (or set of municipalities) i. 
A pre-coded and previously tested ques-
tionnaire was prepared to collect data from the 
clinical charts of selected patients. A manual was 
prepared for completing the questionnaires, and 
training was provided for the field researchers 
and supervisors, who consisted mainly of health 
professionals working in the STD/AIDS Program. 
After completion, the questionnaires were sub-
mitted to two supervisions, one local and the 
other central. 
Data were collected from November 2006 to 
December 2007. For purposes of comparison 
with previous studies 12,13, the decision was made 
not to consider the estimated survival for patients 
that died within 7 days after diagnosis, so no data 
were collected from these patient charts.
For this study, the independent variables 
were: gender, age, race/color, marital status, year 
of diagnosis, schooling, HIV exposure category 
(all of which reported at the time of AIDS diagno-
sis), AIDS-defining diagnostic criterion, presence 
of tuberculosis at diagnosis or during the case 
evolution, Pneumocystis pneumonia (PCP) pro-
phylaxis, hepatitis B and C serology, the results of 
these tests (positive versus negative), use of ART 
(antiretroviral therapy), and care by a multidis-
ciplinary team (annotation on the patient chart 
of having been seen by a professional other than 
physicians or the nursing staff).
In the years 1998 and 1999, the criteria for 
classifying AIDS cases were: CD4 T-cell count (less 
than 350/mm3 independently of symptoms); Rio 
de Janeiro/Caracas criterion, modified CDC cri-
terion (Centers for Disease Control and Preven-
tion), and death 3. The latter was not considered 
in the current study, as mentioned previously.
Positive hepatitis B serology was defined as 
positive for least one of the two serological mark-
ers for this infection, except when only anti-Hbs 
was reactive, which was interpreted as a marker 
of vaccination. 
The dependent variable, survival time, was 
calculated as date of diagnosis to date of death 
for patients that died, and date of diagnosis to 
date of the last visit to the health service for any 
reason for patients that survived, i.e., for those in 
whom there was no record of death. To update 
the information on patient follow-up or death, 
the database for this study was linked to the fol-
lowing national databanks: Mortality Information 
System (SIM), Information System on Laboratory 
Exams (SISCEL), and Logistics Control System for 
Medicines (SICLOM). The databank linkage used 
reclink, and the parameters for comparison were: 
patient’s full name, date of birth, and patient’s 
mother’s full name, and the State of residence 
was not used in the blocking key. The study ex-
cluded patients for whom there was no record 
of having visited the service after diagnosis in ei-
ther the patient charts or the above-mentioned 
databanks.
The study data were keyed into the database 
using Epi Info 6.04 (CDC, Atlanta, USA). 
Patient proportions were estimated accord-
ing to categories of the independent variables, 
and the differences between the two regions 
were evaluated with the chi-square test. Survival 
analysis used the Kaplan-Meier method, also 
used to calculate the percentages of survivors 
for different times since diagnosis. Comparison 
between the categories of study variables in re-
lation to patient survival used Cox regression 
models. Significance for the statistical tests was 
set at 0.05.
Weights were introduced into the data analy-
sis in order to compensate for different patient 
selection probabilities. The analyses used the 
Stata 10 statistical package (Stata Corp., Col-
lege Station, USA) by means of the svy module, 
which allows incorporating aspects referring to 
the sample design (weighting, stratification, and 
cluster selection) in the estimates, except those 
referring to percentages of survivors for given 
times since diagnosis, estimated with the Kaplan-
Meier method. 
The study was approved by the Institution-
al Review Board of the Center for Referral and 
Training in STD/AIDS under the São Paulo State 
Health Department (Case no. 15/05 of June 20, 
2005). It was also approved by research ethics 
committees at various university hospitals and 
some municipal health departments.
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Findings
This study considered 3,130 cases of AIDS pa-
tients, of which 1,150 from the South and 1,980 
from the Southeast of Brazil. It was possible to 
find patient charts and obtain the essential data 
for completing the forms for 2,692 patients (996 
from the South and 1,696 from the Southeast), 
corresponding respectively to 86.6% and 85.7% of 
the cases. Analysis of the data’s consistency led to 
the exclusion of 601 questionnaires due to diag-
nostic dates other than 1998 or 1999; deaths less 
than 7 days after diagnosis; and cases that failed 
to meet any of the AIDS criteria. The final sample 
consisted of 2,091 cases, 782 from the South and 
1,309 from the Southeast, representing, respec-
tively, 68% and 66.1% of the initial sample.
The study population had the following char-
acteristics: most were male (male-to-female ratio 
1.85); 52.7% were diagnosed in 1998; and 54.4% 
had a maximum of complete primary schooling 
(Table 1). The socio-demographic profile dif-
fered in some aspects between the two regions. 
In the South, the patients were younger (34.1% 
were under 30 years of age), showed higher 
proportions of white race/skin color, were mar-
ried or in common-law marriages, and showed 
more exposure from injecting drug use, 29.4% 
compared to 14.9% in the Southeast, although 
the latter showed a higher proportion of missing 
information for exposure category. Importantly, 
the sample did not include any AIDS cases due 
to vertical transmission. The amount of missing 
information was also high for some variables and 
was generally higher in the Southeast. 
As for the diagnostic criterion, co-morbidi-
ties, and treatment: 50.9% were diagnosed based 
on CD4 T-cell count; 25.3% presented tuber-
culosis at the time of AIDS diagnosis or during 
evolution of the disease; 86% used ART; 54.2% 
were tested for hepatitis B, of which 31.7% tested 
positive, and 51.9% were tested for hepatitis C, of 
which 26.7% were positive. In the set of patients, 
16.4% had a diagnosis of hepatitis B (19.3% in the 
Southeast and 11.4% in the South) and 14.1% had 
hepatitis C (12.8% in the Southeast and 18.4% in 
the South); 42.6% had prophylaxis for Pneumo-
cystis jirovecii pneumonia, and 41.4% were treat-
ed at a service with a multidisciplinary health 
team (Table 2). The only significant differences 
between the regions were: a higher rate of posi-
tive serology for hepatitis B in the Southeast and 
hepatitis C in the South.
Patients in the IDU exposure category showed 
the lowest survival probabilities in the two re-
gions (Figure 1). The lowest percentages (below 
50%) of survivors 108 months after diagnosis 
were observed in the IDU exposure category in 
both regions and among black/brown patients 
in the Southeast and widowed individuals in the 
South. The greatest survival rates (proportions of 
survivors greater than 70%) in both regions were 
in patients with more than primary schooling, 
and in the Southeast only, among individuals in 
the MSM (men who have sex with men) sexual 
exposure category (Table 3).
When observing the categories for the vari-
ables related to diagnosis, co-morbidities, and 
treatment, extremely low proportions of survi-
vors (less than 15%) were seen among patients 
not on ART (Table 4). At the other extreme, both 
regions showed survivor rates greater than 70% in 
patients with CD4 T-cell count as the diagnostic 
criterion and those not infected with hepatitis C 
virus. In the Southeast, higher survivor rates were 
also seen in patients tested for hepatitis B and C 
and those with negative hepatitis B serology.
Table 5 shows the univariate analysis, reveal-
ing the mortality risk in both regions was signifi-
cantly higher in males, patients with less school-
ing, in the IDU or missing exposure categories, 
in patients diagnosed according to a criterion 
other than CD4 T-cell count, those not on ART, 
those not tested for hepatitis B or C, and those 
with positive hepatitis C serology. In the South 
only, the risk of dying was also greater in pa-
tients 40 years or older and in single, separated, 
or widowed patients. In the Southeast only, risk 
of dying was greater in black or brown patients 
(hazard ratio - HR = 1.42), those treated in health 
services without other professionals besides 
physicians and nurses, those with a diagnosis of 
tuberculosis (HR = 1.75) sometime during their 
follow-up, those who did not receive Pneumo-
cystis prophylaxis, and those who tested positive 
for hepatitis B. 
Table 6 shows the variables that were main-
tained in the multiple regression model, as as-
sociated with mortality risk. The models for both 
regions maintained the following: gender, school-
ing, ART, and diagnostic criterion. The following 
were also kept in the model in the Southeast only: 
race/color, hepatitis B serology, tuberculosis, and 
having been seen by a multidisciplinary team. 
In the South, the age variable remained in the 
model.
Discussion
This study’s main findings were the survival es-
timates and their determinants in the cohort 
of AIDS patients diagnosed in 1998-1999 in the 
South and Southeast regions of Brazil, after 8-10 
years of follow-up. The study also showed an ev-
ident increase in the survival of these patients 
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Table 1
Socio-demographic and exposure characteristics of AIDS patients. South and Southeast regions of Brazil, 1998-1999 cohort.
Characteristic Southeast South Total p-value *
n % n % n %
Total 1,309 62.6 782 37.4 2,091 100.0
Gender 0.723
Male 853 65.2 504 64.5 1,357 65.0
Female 456 34.8 278 35.5 734 35.0
Age (years) 0.035
13-29 356 27.2 267 34.1 623 28.8
30-39 563 43.0 315 40.3 878 42.4
≥ 40 390 29.8 200 25.6 590 28.8
Race/color 0.001
White 615 47.0 480 61.4 1,095 50.4
Black 86 6.6 71 9.1 157 7.2
Brown 212 16.2 50 6.4 262 13.9
Other 6 0.4 2 0.3 8 0.4
Missing 390 29.8 179 22.9 569 28.2
Marital status 0.007
Single 519 39.7 258 33.0 777 38.1
Married 315 24.1 239 30.6 554 25.6
Common law 81 6.2 67 8.6 148 6.7
Separated 116 8.9 47 6.0 163 8.2
Widowed 67 5.1 28 3.6 95 4.8
Information missing 211 16.1 143 18.3 354 16.6
Year of diagnosis 0.641
1998 686 52.4 419 53.6 1,105 52.7
1999 623 47.6 363 46.4 986 47.3
Schooling 0.844
≤ Primary 672 51.3 505 64.6 1,177 54.4
Secondary/University 309 23.6 225 28.8 534 24.8
Missing 328 25.1 52 6.7 380 20.7
Exposure category 0.001
Sexual 878 67.1 518 66.3 1,396 66.9
IDU 195 14.9 230 29.4 425 18.3
Blood, non-IDU 6 0.5 1 0.1 7 0.4
Missing 230 17.6 33 4.2 263 14.4
IDU: injecting drug user.
* χ2 test performed without the “missing” category and corrected for sampling design.
when compared to previous studies performed 
with a similar design 12,13. Marins et al. 13 found 
a median survival of 58 months when analyzing 
a nationwide patient cohort, diagnosed in 1996, 
while in the current cohort it was not possible to 
calculate the median, since approximately 60% 
of the patients were alive at 108 months after di-
agnosis of the disease. Thus, survival had more 
than doubled in the two years separating one co-
hort from the other. 
In the United States, according to a survival 
study on adults with AIDS diagnosed from 1996 
to 2003, more than 75% of the patients survived 
for at least 108 months 15, although the study 
identified significant variations in the percent-
ages of survivors according to race/ethnicity and 
age bracket. 
Cox multiple regression analysis pointed to 
different models for the Southeast and South 
regions of Brazil, but some variables proved 
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to be strong and consistent predictors in both 
regions: ART, diagnostic criterion, gender, and 
schooling. In the Southeast only, predictors 
of shorter survival included black/brown skin 
color as an indicator of lower socioeconomic 
status; co-morbidities like hepatitis B and his-
tory of tuberculosis; and a services organization 
variable, namely the presence of a multidisci-
plinary team. In the South, age remained in the 
final model. 
Several of these predictors have also been 
identified by other authors in Brazil and else-
where in the world 16,17,18,19,20.
The categories “use of ART” and “CD4 count 
as the diagnostic criterion” were consistently as-
sociated with longer survival in the South and 
Southeast, independently of gender and school-
ing. This indicates access to health services and 
antiretroviral therapy and early diagnosis. AIDS 
diagnosis according to CD4 T-cell count is more 
sensitive, captures patients earlier, and allows 
access to early preventive and therapeutic inter-
ventions. Late diagnosis of the disease has been 
identified as a predictor of mortality, even before 
the incorporation of the CD4 criterion by health 
services in Brazil 12. 
Table 2
AIDS patients according to diagnosis, co-morbidity, and treatment. South and Southeast regions, 1998-1999 cohort.
Characteristic Southeast South Total p-value *
n % n % n %
Total 1,309 62.6 782 37.4 2,091 100.0
Diagnostic criterion 0.183
Modified CDC 338 25.8 173 22.1 511 24.9
Rio de Janeiro/Caracas 263 20.1 217 27.7 480 21.9
CD4 T-cell count 671 51.3 388 49.6 1,059 50.9
Missing 37 2.8 4 0.5 41 2.3
Tuberculosis 0.206
Yes 965 26.3 608 22.3 518 25.3
No 344 73.7 174 77.7 1,573 74.7
ART 0.526
Yes 1,116 85.3 692 88.5 1,808 86.0
No 111 8.5 59 7.5 170 8.3
Missing 82 6.3 31 4.0 113 5.7
HBV serology 0.3614
Tested 739 56.5 394 50.4 1,133 54.2
Not tested/Not recorded 570 43.5 388 49.6 958 45.0
HBV test result 0.0334
Positive 253 34.2 89 22.6 342 31.7
Negative 486 65.8 305 77.4 791 68.3
HCV serology 0.8166
Tested 689 52.6 397 50.8 1,086 51.9
Not tested/Not recorded 620 47.4 385 49.2 1,005 47.8
HCV test result 0.0097
Positive 167 24.2 144 36.3 311 26.7
Negative 522 75.8 253 63.7 775 73.0
PCP prophylaxis 0.779
Reported 552 42.2 345 44.1 897 42.6
Not reported 757 57.8 437 55.9 1.194 57.4
Multidisciplinary team 0.852
Yes 537 41.0 333 42.6 870 41.4
No 772 59.0 449 57.4 1.221 58.6
* χ2 test performed without the “missing” category and corrected for sampling design.
ART: antiretroviral therapy; CDC: Centers for Disease Control and Prevention; HBV: hepatitis B virus; HCV: hepatitis C virus; 
PCP: Pneumocystis pneumonia.
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The availability of highly active antiretrovi-
ral therapy and adherence to the treatment regi-
men have been highlighted by various authors 
as essential for the effectiveness of individual 
treatment, besides decreasing the spread of vi-
ral resistance at the collective level. Meanwhile, 
the organization of health services and the com-
prehensive approach to patients can be decisive 
in improving clinical follow-up and improved 
treatment adherence, resulting longer survival 
7,18,21,22.
As for exposure category, survival was shorter 
among IDUs in both regions. Various authors 
have identified late diagnosis of the disease, diffi-
culties in clinical follow-up, and lower treatment 
adherence as determinants of shorter survival in 
these patients 23,24. There was a higher propor-
tion of “missing” information on this variable in 
the Southeast when compared to the South, as 
observed in the National STD/AIDS Program 25, 
where the category “missing” accounts for 12% of 
the total for the country (13.1% in the Southeast 
and 9% in the South).
According to the bivariate analysis, the find-
ings in this 1998-1999 cohort point to higher 
mortality in males in both regions. Importantly, 
there was a major spread of the disease among 
IDU in the South, a group consisting mostly of 
young men. Longer survival in women could 
result from greater enrollment in (and use of) 
health services and prenatal care and childbirth 
(which increase the probability of performing 
diagnostic tests), and thus earlier diagnosis of 
HIV infection or AIDS. According to some stud-
Figure 1
Percentage of individuals surviving with AIDS, according to exposure category. South and Southeast regions of Brazil, 1998-1999 cohort.
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Table 3
Percentage of AIDS patients with survival of at least 108 months and respective 95% confi dence intervals (95%CI), according 
to geographic region and demographic and exposure characteristics. 1998-1999 cohort.
Characteristic Southeast South
% 95%CI % 95%CI
Total 59.5 56.3-62.5 59.3 55.5-63.0
Gender
Male 56.4 52.4-60.2 55.2 50.3-59.8
Female 65.2 59.9-70.0 66.7 60.2-72.4
Age (years)
13-29 61.3 55.2-66.7 64.1 57.4-70.0
30-39 59.9 54.8-64.6 58.0 51.8-63.7
≥ 40 57.3 51.5-62.6 55.1 49.4-62.2
Race/color
White 61.2 56.6-65.4 60.6 55.7-65.1
Black/Brown 46.6 39.5-53.4 54.8 44.5-64.0
Marital status
Single 60.1 55.0-64.8 50.1 43.2-56.5
Married 63.6 56.9-69.5 63.2 56.4-69.2
Common law 60.8 48.1-71.3 68.0 55.2-77.8
Separated 63.6 53.2-72.3 61.0 44.8-73.7
Widowed 58.3 45.0-69.5 49.9 18.075.4
Year of diagnosis
1998 57.3 53.0-61.3 55.8 50.7-60.7
1999 63.8 59.6-67.7 64.4 58.8-69.4
Schooling
≤ Complete primary 55.3 50.7-59.6 54.7 49.9-59.3
Complete secondary/University 70.2 64.0-75.6 73.3 65.9-79.3
Exposure category
Heterosexual, men 58.8 51.9-64.9 64.7 55.6-72.4
Sexual, MSM 72.0 65.3-77.7 61.0 51.0-69.6
Heterosexual, women 69.8 63.9-74.9 68.9 61.8-74.9
IDU 42.2 33.6-50.5 48.6 41.6-55.2
IDU: injecting drug users; MSM: men who have sex with men.
ies, the association between gender and risk of 
dying is not maintained after controlling for so-
cioeconomic variables and access to health ser-
vices 1,13,17.
Schooling was analyzed as a marker of the 
population’s socioeconomic conditions, and was 
the only such information available on the pa-
tient chart disease notification forms. Individuals 
with complete secondary or university education 
showed lower risk of dying, compared to those 
with less schooling or with this information miss-
ing (the statistical significance remained in the 
final model in both regions). Higher AIDS mor-
tality has been recorded in poor populations and 
countries, even with access to HAART. Factors 
possibly related to this excess risk include later 
diagnosis, higher prevalence of co-morbidities 
due to chronic invasive infections like tuber-
culosis, mycoses, and others, and more limited 
understanding and conditions to adhere to pro-
longed treatment, compared to population seg-
ments with higher schooling 7,19. 
In the Southeast, even after adjusting for 
schooling, longer survival was shown in white in-
dividuals as compared to black or brown. The race/
color variable (self-reported) was only incorpo-
rated into the AIDS investigation form in 2001 26. 
It is thus difficult to analyze trends, although 
recent years have seen a clear improvement in 
completion of the data: in 2000, 96% of reported 
AIDS cases lacked this information, whereas this 
proportion of missing information on race/color 
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dropped to only 15% by 2005 26,27. In the South, 
even in the bivariate analysis, the race/color vari-
able was not associated with survival. 
Various authors have called attention to the 
difference in the risk of dying from AIDS accord-
ing to race/skin color and ethnicity, attributing 
these differences to inequalities in access to 
health services and antiretroviral therapy, expo-
sure to other diseases, and differences in living 
conditions. In Brazil, few studies have investigat-
ed this issue in depth 16,27,28,29. 
Fifty-two percent of patients in the sample 
had tested for hepatitis C, among whom 14% 
were seropositive, with no differences between 
the regions. This proportion of individuals tested 
for HCV was higher than observed in the study 
by Marins 30 (29,5%), a difference that may result 
from the increase in survival, allowing more op-
portunities for performing HCV serology, besides 
indicating improved care. Prevalence of co-infec-
tion in that cohort (1995-1996) was 33.4%, while 
in the current study (1998-1999 cohort) it was 
26.7%. The decrease in the proportion of AIDS 
cases among drug users in the last decade may 
have influenced this trend.
In relation to hepatitis B, 54% of the patients 
had done serological tests, of which 31.7% tested 
positive. In both regions, increased survival was 
related to fact that patients had been tested for 
hepatitis B and C. Early serological testing may 
Table 4
Percentage of AIDS patients with survival of at least 108 months according to diagnosis, co-morbidities, and treatment, and 
respective 95% confi dence intervals (95%CI). 1998-1999 cohort.
Characteristic Southeast South
% 95%CI % 95%CI
Diagnostic criterion
Modified CDC 52.1 46.0-57.8 45.6 37.8-53.1
Rio de Janeiro/Caracas 38.5 31.1-45.9 48.7 41.4-55.5
CD4 T-cell count 71.2 66.9-75.1 71.4 65.9-76.2
Tuberculosis
Yes 45.7 39.4-51.8 49.7 41.7-57.1
No 64.2 60.6-67.6 62.1 57.7-66.2
ART
Yes 67.2 63.9-70.3 63.5 59.4-67.3
No 14.4 7.8-23.0 10.5 3.8-21.1
HBV serology
Tested 73.7 69.8-77.2 67.9 62.6-72.6
Not tested/Not recorded 39.7 34.8-44.6 50.3 44.7-55.7
HBV test result
Positive 69.7 62.6-75.8 63.5 52.2-72.8
Negative 75.8 71.0-80.0 69.2 63.2-74.5
HCV serology
Tested 75.1 71.1-78.7 67.4 62.1-72.1
Not tested/Not recorded 41.0 36.2-45.6 50.7 45.1-56.1
HCV test result
Positive 65.4 55.4-73.6 60.9 52.0-68.6
Negative 78.2 73.8-81.9 71.1 64.5-76.8
PCP prophylaxis
No/not  recorded 53.9 49.7-57.9 62.5 57.5-67.2
Yes 67.1 62.2-71.5 55.5 49.6-61.1
Multidisciplinary team
No 52.6 48.4-56.6 57.7 55.7-67.3
Yes 69.1 64.2-73.5 61.8 52.7-62.3
ART: antiretroviral therapy; CDC: Centers for Disease Control and Prevention; HBV: hepatitis B virus; HCV: hepatitis C virus; 
PCP: Pneumocystis pneumonia.
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Table 5
Hazard ratio (HR) estimates according to AIDS patients’ characteristics. South and Southeast regions, 1998-1999 cohort.
Characteristic Southeast South
HR p-value HR p-value
Gender
Male 1 1
Female 0.745 0.002 0.652 0.016
Age (years)
13-29 1 1
30-39 0.982 0.877 1.193 0.187
≥ 40 1.169 0.173 1.417 0.030
Schooling 
≤ Primary 1 1
Secondary/University 0.617 0.001 0.485 0.000
Missing 1.024 0.889 1.667 0.099
Race/color 
White 1 1
Black/brown 1.421 0.009 1.180 0.254
Missing 0.844 0.178 1.153 0.562
Exposure category
Sexual 1 1
IDU 1.872 0.000 1.762 0.000
Blood (non IDU) + missing 1.971 0.000 3.465 0.002
Diagnostic criterion
Modified CDC 1 1
Rio de Janeiro/Caracas 1.289 0.057 0.868 0.234
CD4 T-cell count 0.417 0.000 0.344 0.000
Missing 1.101 0.831 0.651 0.006
ART
Yes 1 1
No 10.209 0.000 8.328 0.000
Missing 4.473 0.001 1.760 0.183
Multidisciplinary team
No 1 1
Yes 0.515 0.001 0.771 0.166
Year of diagnosis
1998 1 1
1999 0.910 0.356 0.769 0.205
Marital status
Single 1 1
Married 0.840 0.296 0.672 0.031
Common law 0.942 0.695 0.602 0.024
Separated 0.881 0.436 0.775 0.330
Widowed 1.004 0.987 0.635 0.262
Information missing 1.332 0.244 0.603 0.048
HBV serology
Not tested/Not recorded 1 1
Tested 0.297 0.000 0.525 0.003
(continues)
SURVIVAL OF PATIENTS IN THE 1998-1999 AIDS COHORT S89
Cad. Saúde Pública, Rio de Janeiro, 27 Sup 1:S79-S92, 2011
Table 5 (continued)
Characteristic Southeast South
HR p-value HR p-value
HBV test result
Positive 1 1
Negative 0.732 0.045 0.795 0.183
Not tested/Not recorded 2.768 0.000 1.601 0.000
HCV serology
Not tested/Not recorded 1 1
Tested 0.288 0.000 0.550 0.022
HCV test result
Positive 1 1
Negative 0.671 0.008 0.671 0.032
Not tested/Not recorded 2.602 0.000 1.428 0.132
Tuberculosis
No 1 1
Yes 1.756 0.000 1.449 0.073
PCP prophylaxis
No 1 1
Yes 0.572 0.005 1.119 0.585
ART: antiretroviral therapy; CDC: Centers for Disease Control and Prevention; IDU: injecting drug user; HBV: hepatitis B virus; 
HCV: hepatitis C virus; PCP: Pneumocystis pneumonia.
Table 6
Results of Cox multiple regression analysis, indicating variables associated with survival of AIDS patients in the Southeast and 
South of Brazil, 1998-1999 cohort.
Variables Southeast South
HR p-value HR p-value
Gender
Male 1 1
Female 0.78 0.042 0.61 0.002
Schooling
≤ Primary 1 1
Secondary/University 0.61 0.004 0.53 0.001
Missing 0.75 0.105 1.67 0.042
Age (years)
13-29 1
30-39 1.05 0.721
≥ 40 1.43 0.007
Race/color
White 1
Black 1.44 0.021
Brown 1.33 0.034
Missing 0.72 0.040
ART
Yes 1 1
No 6.42 0.000 6.77 0.000
Missing 2.23 0.001 1.96 0.085
(continues)
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be associated with increased survival, and re-
cording serological results on the patient chart 
may reflect better quality of care. Importantly, 
there was an increased risk of mortality in pa-
tients co-infected with hepatitis B as compared 
to HBV-negative patients, even after adjusting for 
all the other variables included in the final model 
in the Southeast region. Various studies cited by 
Ferreira & Borges 31 demonstrated greater risk 
of dying in patients with HIV/HBV co-infection, 
especially in those with low CD4 T-lymphocyte 
counts, as well as chronic alcoholics.
HIV/TB co-infection only contributed to re-
duction in survival in the Southeast. Other stud-
ies have reported worse AIDS prognosis in the 
presence of tuberculosis 11,30,32.
In the Southeast, AIDS mortality was lower in 
patients attending health services with a multi-
disciplinary team, i.e., with nutritionists, physical 
therapists, psychologists, and other profession-
als. The healthcare system in this region has a 
better infrastructure, with a consolidated system 
for distribution of medicines, as compared to 
other regions of Brazil. According to data from 
QUALIAIDS, in the South, 22.1% of services are 
classified as having better quality, while in the 
Southeast the proportion is 32/.2% 33. In an eval-
uation on quality of care for patients with HIV/
AIDS in seven Brazilian States, Melchior et al. 34 
highlight the importance of having such profes-
sionals (in addition to physicians and nurses) in 
the health teams, even though these services are 
accessed mainly through referral by the attend-
ing physician.
One of the current study’s limitations is that 
it analyzed secondary data, obtained from pa-
tient charts, implying a variation in quality, loss 
of data, and lack of data completeness. However, 
the calculated sample considered the possibility 
of losses, and the number of completed ques-
tionnaires allowed estimates with an adequate 
degree of precision that can be compared to pre-
vious studies, and to evaluate the increase in sur-
vival over time.
Despite major social disparities between 
Brazil’s geographic regions and different AIDS 
transmission dynamics, this study points to an 
important gain in survival in patients with AIDS 
diagnosis in the two regions studied here: ap-
proximately 60% of the AIDS patients survived 
for at least 108 months. The findings also show 
persistent major challenges common to both 
the South and Southeast, including expansion of 
access to therapy and upgrading of healthcare 
services.
Table 6 (continued)
Variables Southeast South
HR p-value HR p-value
Diagnostic criterion
Modified CDC 1 1
Rio de Janeiro/Caracas 1.13 0.470 0.84 0.096
CD4 T-cell count 0.61 0.006 0.41 0.000
Missing 0.81 0.527 0.62 0.002
HBV serology
Positive 1
Negative 0.77 0.040
Not tested/Not recorded 1.91 0.000
Multidisciplinary team
Yes 1
No 1.44 0.001
Tuberculosis
No 1
Yes 1.60 0.003
ART: antiretroviral therapy; CDC: Centers for Disease Control and Prevention; HBV: hepatitis B virus; HR: hazard ratio.
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Resumo
O estudo objetivou avaliar o tempo de sobrevida de 
pacientes de AIDS, com 13 anos ou mais de idade, das 
regiões Sul e Sudeste do país, segundo características 
sóciodemográficas e clínico-epidemiológicas. A amos-
tra foi sorteada a partir da totalidade dos casos notifi-
cados no Sistema de Vigilância Epidemiológica do Pro-
grama Nacional de DST/AIDS, diagnosticados em 1998 
e 1999. Utilizando-se questionário foi possível analisar 
2.091 prontuários médicos. Pelo método Kaplan-Meier, 
foi estimada sobrevivência de pelo menos 108 meses 
após o diagnóstico em 59,5% dos pacientes no Sudeste 
e 59,3% no Sul. Por meio de modelos de regressão de 
Cox, foi verificado, nas duas regiões, aumento da so-
brevivência nos pacientes que usaram antirretrovirais, 
que foram classificados como caso de AIDS pelo crité-
rio CD4, que eram do sexo feminino e com maior es-
colaridade. Os fatores associados a tempos maiores de 
sobrevida no Sudeste foram ainda: possuir cor da pele 
branca, não ter tido tuberculose após seu diagnóstico 
de AIDS, não ser reagente à hepatite B e ter tido acesso 
à equipe multidisciplinar. No Sul, ter idade abaixo de 
40 anos possibilitou maior sobrevida.
Síndrome de Imunodeficiência Adquirida; Sobrevida; 
Anti-Retrovirais; Mortalidade
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